Glucosamine chondroitin is the best-selling supplement combination for joints, especially after 50, when knee osteoarthritis sets in. What do the trials run since 2001 on more than 9,000 patients really show? Here are the results in figures, the dose tested and the precautions to know before starting a course.
In brief – Glucosamine chondroitin is a combination of two natural components of cartilage, sold to relieve osteoarthritis of the knee and hip. The large independent trials give a modest result: in GAIT (1,583 patients, 6 months), neither molecule did better than placebo across all participants. A meta-analysis of 3,803 patients puts the gain at 0.4 cm on a 10 cm pain scale, below the threshold a patient can feel. A few industry-funded trials using pharmaceutical forms are more favorable. The dose studied is 1,500 mg of glucosamine and 800 to 1,200 mg of chondroitin per day, to be assessed after three to six months. The combination is well tolerated, but it calls for caution in people taking warfarin and in those with a shellfish allergy.
Glucosamine chondroitin: definition
Glucosamine chondroitin refers to taking two molecules together that occur naturally in joint cartilage. Glucosamine is an amino sugar that the body makes from glucose. Chondroitin sulfate is a long chain of sugars, called a glycosaminoglycan, which gives cartilage its ability to hold water and absorb shocks.
In France, these substances come under two different statuses. Some pharmaceutical products were classed as symptomatic slow-acting drugs for osteoarthritis, which the national health insurance stopped reimbursing in March 2015. The others are sold as dietary supplements, with content and manufacturing quality that vary more from one brand to the next.
Osteoarthritis affects about 528 million people worldwide according to the World Health Organization, including 365 million for the knee alone. This is the population that buys most of the glucosamine and chondroitin supplements on the market.
What glucosamine chondroitin contains and how it is supposed to work
On paper, the goal is simple: supply cartilage with its own building materials. Cartilage is a tissue without blood vessels, made of cells called chondrocytes embedded in a matrix of collagen and proteoglycans. With age and osteoarthritis, this matrix thins out and loses water.
- Glucosamine is the basic building block of glycosaminoglycans. It comes as a sulfate (the form used in the European trials) or as a hydrochloride (the form used in the American GAIT trial).
- Chondroitin sulfate is extracted from bovine, pig, chicken or shark cartilage. Its purity varies widely depending on the source and the manufacturing process.
- Commercial glucosamine most often comes from shellfish shells, and sometimes from corn fermentation for the plant-based versions.
- In the lab, both molecules slow down enzymes that break down cartilage, as well as inflammatory signals. In humans, the amount that actually reaches the joint after digestion is still debated.
This last point explains the gap between the logic of the mechanism and the clinical results. Swallowing cartilage does not guarantee that cartilage will rebuild: the supplement has to cross the gut, the liver and the bloodstream before reaching a tissue with a poor blood supply. To understand what really wears down the joint, our article on knee cartilage and exercise explains what MRI scans actually measure.
What the science says about glucosamine chondroitin
The largest independent trials show no clear benefit of glucosamine chondroitin on knee osteoarthritis pain, whereas several trials funded by manufacturers are positive. This divergence shapes the entire body of evidence.
Independent trials: a small effect or none at all
The American GAIT trial (Clegg et al., 2006) randomized 1,583 patients with a mean age of 59 to glucosamine hydrochloride (1,500 mg), chondroitin (1,200 mg), both, celecoxib or a placebo for 24 weeks. The response rate on placebo reached 60.1%. The combination did only 6.5 points better, a difference that was not statistically significant. Only a subgroup of 354 patients with moderate to severe pain responded better (79.2% versus 54.3%), an exploratory lead and not proof.
The two-year follow-up of 662 participants (Sawitzke et al., 2010) found no clinically important difference in pain or in function. The network meta-analysis by Wandel et al., 2010 (10 trials, 3,803 patients) puts the gain from the combination at 0.5 cm on a 10 cm scale, below the 0.9 cm threshold considered noticeable. In that analysis, trials independent of industry showed smaller effects than commercially funded trials.
In Australia, the LEGS trial (Fransen et al., 2015, 605 participants aged 45 to 75, two years) found no benefit on pain compared with placebo. The combination slowed joint space narrowing by 0.10 mm, a borderline statistical result (p = 0.046). In Spain, Roman-Blas et al., 2017 (164 patients, six months) even observed a larger drop in pain on placebo (33%) than on glucosamine plus chondroitin (19%).
Favorable trials: pharmaceutical forms and industry funding
The positive results come mainly from crystalline glucosamine sulfate and pharmaceutical-grade chondroitin. Over three years, Reginster et al., 2001 (212 patients) measured a joint space loss of 0.31 mm on placebo versus 0.06 mm on glucosamine sulfate. Pavelká et al., 2002 (202 patients) found a difference of the same order. The CONCEPT trial (Reginster et al., 2017, 604 patients) put chondroitin at 800 mg on a par with celecoxib, with a drop in pain of 42.6 mm versus 33.3 mm on placebo.
The MOVES trial (Hochberg et al., 2016, 606 patients with severe pain) compared glucosamine plus chondroitin with celecoxib without a placebo group: both arms reduced pain by about 50%, a figure that therefore includes the placebo effect. The Cochrane review on chondroitin (Singh et al., 2015, 43 trials, 9,110 participants) concluded to a gain of 8 points out of 100 in the short term, based on trials that were mostly of low quality.
| Study | Participants | Duration | Main result |
|---|---|---|---|
| GAIT, Clegg 2006 | 1,583 | 6 months | Combination not superior to placebo (+6.5 points, not significant) |
| Wandel 2010, meta-analysis | 3,803 | 10 trials | Gain of 0.5 cm out of 10, below the noticeable threshold |
| LEGS, Fransen 2015 | 605 | 2 years | Pain unchanged, narrowing reduced by 0.10 mm |
| Roman-Blas 2017 | 164 | 6 months | Placebo better on pain (33% versus 19%) |
| Reginster 2001 | 212 | 3 years | Joint space preserved (0.06 mm versus 0.31 mm lost) |
| CONCEPT, Reginster 2017 | 604 | 6 months | Chondroitin 800 mg equal to celecoxib, better than placebo |
Beyond the knee, the Norwegian trial by Wilkens et al., 2010 (250 patients with chronic low back pain and lumbar osteoarthritis) found no effect of 1,500 mg of glucosamine on disability, either at six months or at one year.
Glucosamine chondroitin and longevity: associations, not proof
Two analyses of the British UK Biobank cohort have revived interest in glucosamine from a longevity angle. Among 466,039 adults without cardiovascular disease, Ma et al., 2019 linked habitual glucosamine use to 15% fewer cardiovascular events (HR 0.85). In 495,077 participants followed for 8.9 years, Li et al., 2020 reported 15% lower all-cause mortality (HR 0.85).
These figures describe an association, not cause and effect. Regular supplement users often have a healthier lifestyle, more physical activity and better medical follow-up, which statistical adjustments never fully correct for. Chondroitin was not studied separately in these analyses. No randomized trial has tested these supplements as a way to extend life: taking it for that purpose goes beyond what science can claim.
The link between osteoarthritis and aging runs mostly through immobility, a sedentary lifestyle and chronic inflammation. Our feature on osteoarthritis and longevity explains why keeping your joints mobile weighs on healthy life expectancy.
In practice: who might consider glucosamine chondroitin?
The combination can be discussed for an adult with knee or hip osteoarthritis and moderate pain, who already does suitable exercise and wants to try a well-tolerated option. It replaces neither muscle strengthening nor weight loss, which all guidelines put first.
Medical societies remain cautious about these supplements. The OARSI guidelines (Bannuru et al., 2019) put education and exercise first in line and do not recommend glucosamine or chondroitin. Those of the American College of Rheumatology (Kolasinski et al., 2020) give only a conditional recommendation to chondroitin, and only for hand osteoarthritis. As the NHS points out, osteoarthritis is a long-term condition that cannot be cured, and no treatment is able to rebuild cartilage.
| Form | Dose studied per day | Level of evidence | Watch point |
|---|---|---|---|
| Crystalline glucosamine sulfate | 1,500 mg in a single dose | Positive trials, mostly funded by the manufacturer | Form used in the European studies |
| Glucosamine hydrochloride | 1,500 mg | No effect in GAIT or in Wilkens | Common form in supplements |
| Pharmaceutical chondroitin sulfate | 800 to 1,200 mg | Modest gain at 6 months (CONCEPT, Cochrane) | Highly variable quality outside pharmacies |
| Glucosamine plus chondroitin combination | 1,500 mg + 1,200 mg | Conflicting results (GAIT, LEGS, Roman-Blas) | Higher cost with no clear gain |
Collagen is often sold on the same shelves. Its evidence is different and is covered in our article on collagen for skin and joints. The prevention angle stays the same: protecting cartilage starts with daily movement and a healthy weight.
Protocol and precautions before a glucosamine chondroitin course
A course should be run like a personal test: a quality product, the dose used in the trials, a limited duration, then a decision based on how you actually feel. Here are the benchmarks drawn from the studies and from drug safety (pharmacovigilance) reports.
- Dose: 1,500 mg of glucosamine and 800 to 1,200 mg of chondroitin per day, the amounts tested in GAIT, CONCEPT and LEGS.
- Evaluation period: take stock at three months, then at six months. Without a clear improvement in pain, stop.
- Quality: choose a pharmaceutical product or a supplement that states the source and the exact chondroitin content.
- Anticoagulants: if you take warfarin, tell your doctor and have your INR checked, because Knudsen and Sokol, 2008 identified 20 FDA reports of disrupted blood clotting.
- Shellfish allergy: choose a plant-based glucosamine and ask for medical advice.
- Diabetes: monitor your blood sugar at the start of the course, since glucosamine is an amino sugar.
- Pregnancy and breastfeeding: avoid it, for lack of safety data.
Glucosamine chondroitin remains well tolerated: in GAIT as in LEGS, side effects were rare and evenly spread between the groups, mostly mild digestive complaints. Our cellular senescence pillar brings together our features on how tissues wear with age.
| Situation | Documented risk | What to do |
|---|---|---|
| Warfarin treatment | Increased INR (21 WHO cases, 17 reversible on stopping) | Medical advice and INR monitoring |
| Shellfish allergy | Possible traces of proteins | Plant-based glucosamine, allergist’s advice |
| Diabetes | Effect on blood sugar unlikely but worth checking | Blood sugar checks in the first weeks |
| Pregnancy, breastfeeding | No data | Do not take it |
To receive our monthly analyses on supplements and prevention, sign up for our health newsletter.
Frequently asked questions about glucosamine chondroitin
What is the difference between glucosamine and chondroitin?
Glucosamine is an amino sugar, a precursor of the chains that hold water in cartilage. Chondroitin sulfate is one of those chains, already assembled. The first comes mainly from shellfish shells or fermented corn, the second from bovine, pig, poultry or shark cartilage. Trials test the two molecules together or each one alone, at 1,500 mg and 800 to 1,200 mg per day.
How long should you take glucosamine chondroitin before judging the effect?
Clinical trials measure the effect on pain after 24 weeks, or about six months. An honest review therefore happens around three months, then again at six months. If pain and day-to-day discomfort have not changed by then, continuing the course has no proven benefit: it is better to talk to your doctor and focus on exercise.
Is it safe to take glucosamine and chondroitin with an anticoagulant?
Caution is needed with vitamin K antagonists such as warfarin. An FDA review identified 20 reports of disrupted clotting in patients combining warfarin and glucosamine, and the WHO database 21 cases of increased INR, 17 of which returned to normal after stopping. Anyone on an anticoagulant should tell their doctor before starting and have their INR checked.
Why are glucosamine and chondroitin no longer reimbursed in France?
Since March 1, 2015, symptomatic slow-acting drugs for osteoarthritis, including glucosamine and chondroitin, are no longer reimbursed in France. The Transparency Committee of the HAS, the French National Authority for Health, judged their medical benefit insufficient: a minimal effect on pain and no solid evidence that they slow osteoarthritis. They are still sold in pharmacies and as supplements.
Can you take glucosamine if you have a seafood allergy?
Most glucosamine is extracted from shrimp or crab shells. The allergy targets shellfish proteins, which are normally removed during purification, but the risk of traces is not zero. People with this allergy choose a plant-based glucosamine, made by fermenting corn, and ask an allergist for advice if they have a history of severe reactions.
Medical disclaimer. The information on this page is provided for informational purposes only and does not constitute medical advice. It does not replace a consultation. Ask a healthcare professional before changing your diet, taking dietary supplements or starting a new practice, especially if you have a medical condition, are pregnant or are under treatment. Dietary supplements do not replace a balanced diet or medical follow-up.
